Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Operating activities
Net loss	$ (292,876)	$ (350,544)	$ (285,620)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	3,000	3,102	2,410
Amortization of operating lease right-of-use assets	3,224
Accretion of discount on investment securities	(1,225)	(1,864)	(235)
Non-cash interest expense	25,371	18,740	11,603
Stock-based compensation expense, net of capitalized labor	52,075	55,360	43,284
Charge associated with our Gen 1 manufacturing process transition	0	10,311	0
Remeasurement (gain) loss on embedded derivatives liabilities	(2,931)	(6,357)	4,562
Provision for excess and obsolete inventories	4,152	2,246	0
Loss on impairment and provision for excess and obsolete inventories of Bevyxxa asset group	27,451	0	0
Loss on impairment of SRX intangible asset	3,151	0	0
Others	195	15	52
Changes in operating assets and liabilities:
Inventories	(58,830)	(12,612)	(1,099)
Trade and other receivables, net	(7,698)	607	(3,750)
Unbilled - collaboration and license revenue	6,097	(3,186)	0
Prepaid and other current assets	3,812	(7,496)	235
Prepaid and other long-term assets	(3,813)	(10,968)	(4,395)
Accounts payable	(2,652)	1,881	(5,242)
Accrued research and development	(582)	(25,142)	21,155
Accrued and other liabilities	17,668	3,514	8,576
Deferred revenue	(360)	(1,288)	(15,796)
Notes payable and long term royalty-based debt	(13,152)	(1,412)	0
Other long-term liabilities	0	(965)	(865)
Net cash used in operating activities	(237,923)	(326,058)	(225,125)
Investing activities
Capital expenditures, net	(1,544)	(2,559)	(1,236)
Purchase of intangible assets	0	0	(5,000)
Purchases of investments	(368,747)	(259,083)	(575,624)
Proceeds from maturities of investments	297,289	435,723	353,088
Net cash (used in) provided by investing activities	(73,002)	174,081	(228,772)
Financing activities
Proceeds from debt issuance, net	121,703	95,000	47,444
Proceeds from issuance of common stock from public offering, net	243,941	0	379,894
Proceeds from issuance of common stock pursuant to equity award plans	24,896	15,389	19,642
Payments of long-term obligation to collaborator	(976)	0	0
Other	0	(140)	0
Net cash provided by financing activities	389,564	110,249	446,980
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2)	0	0
Net increase (decrease) in cash, cash equivalents and restricted cash	78,637	(41,728)	(6,917)
Cash, cash equivalents and restricted cash at beginning of period	140,013	181,741	188,658
Cash, cash equivalents and restricted cash at end of period	$ 218,650	$ 140,013	$ 181,741